Drug From Genentech and Biogen Fails as a Lupus Treatment
April 29th, 2008 at 7:00 pm (Autoimmune Diseases, Biogen Idec Incorporated|BIIB|NASDAQ, Biotechnology, Drugs (Pharmaceuticals), Genentech Inc|DNA|NYSE, Lupus (Disease), Medicine and Health)
The companies said that their drug Rituxan did not achieve any of seven measures of effectiveness in a late-stage patient trial.
Zrodlo (oryginalny wpis) na http://www.nytimes.com/2008/04/30/business/30drug.html?partner=rssnyt&emc=rss,By ANDREW POLLACK